Exiqon A/S (NASDAQ OMX Copenhagen: “EXQ”) today announced that
Fondsmægler-selskabet LD Invest A/S has informed the company pursuant to
section 29 of the Danish Securities Trading Act, that The Professional
Association LD (PLD) has decreased its shareholding and now holds under 5% of
the share capital and the voting rights in Exiqon A/S.
Additional information
Lars Kongsbak, President and CEO, tel. +45 4566 0888 (cell:+45 4090 2101)
Hans Henrik Chrois Christensen, CFO, tel. +45 4566 0888 (cell: +45 4090 2131)
About Exiqon
Exiqon's products are based on the proprietary LNA™ technology. This technology
offers unique advantages for detection of miRNA biomarkers for life science
researchers, drug developers and cancer treating physicians working towards
personalizing medicine. Exiqon operates in two business areas: Exiqon Life
Sciences has established a position for itself as one of the market's leading
providers of miRNA research products for miRNA analysis in cells. Our research
products are used by academia, biotech and pharmaceutical companies around the
world to make groundbreaking discoveries about the correlation between gene
activity and the development of cancer and other diseases. Exiqon Life Sciences
is also collaborating with pharmaceutical companies in their effort to develop
new medicines based on miRNA as biological markers (Exiqon Pharma Services).
Exiqon Diagnostics collaborates with pharmaceutical and diagnostic companies to
develop novel molecular diagnostic tests for early detection of diseases which
can help physicians make treatment decisions. Exiqon is listed on the NASDAQ
OMX in Copenhagen. For more information about us, please visit www.exiqon.com.
See the announcement in the attached pdf-document.
